Coherus Oncology, Inc.

Coherus Oncology, Inc.verified

CHRS

Price:

$1.23

Market Cap:

$142.57M

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody ...[Read more]

Industry

Biotechnology

IPO Date

2014-11-06

Stock Exchange

NASDAQ

Ticker

CHRS

The ROE as of December 2025 (TTM) for Coherus Oncology, Inc. (CHRS) is -574.72%

According to Coherus Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -574.72%. This represents a change of -929.14% compared to the average of 69.31% of the last 4 quarters.

Coherus Oncology, Inc. (CHRS) Historical ROE (quarterly & annually)

How has CHRS ROE performed in the past?

The mean historical ROE of Coherus Oncology, Inc. over the last ten years is 247.90%. The current -574.72% ROE has changed -331.83% with respect to the historical average. Over the past ten years (40 quarters), CHRS's ROE was at its highest in in the March 2018 quarter at 2.47%. The ROE was at its lowest in in the March 2022 quarter at -885.48%.

Quarterly (TTM)
Annual

Average

247.90%

Median

66.22%

Minimum

-779.99%

Maximum

3.22%

Coherus Oncology, Inc. (CHRS) ROE by Quarter and Year

Discovering the peaks and valleys of Coherus Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 18.55%

Maximum Annual ROE = 3.22%

Minimum Annual Increase = -2568.62%

Minimum Annual ROE = -779.99%

Quarterly (TTM)
Annual
YearROEChange
2024-21.60%-117.56%
2023122.99%-42.07%
2022212.31%-172.27%
2021-293.78%-724.18%
202047.07%-44.88%
201985.38%-84.26%
2018542.46%-169.55%
2017-779.99%18.55%
2016-657.94%-120.42%
20153.22%-2568.62%

Coherus Oncology, Inc. (CHRS) Average ROE

How has CHRS ROE performed in the past?

The current ROE of Coherus Oncology, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

104.57%

5-year avg

13.40%

10-year avg

247.90%

Coherus Oncology, Inc. (CHRS) ROE vs. Peers

How is CHRS’s ROE compared to its peers?

Coherus Oncology, Inc.’s ROE is greater than OmniAb, Inc. (-23.14%), greater than Invivyd, Inc. (-92.97%), greater than SELLAS Life Sciences Group, Inc. (-132.51%), greater than Codexis, Inc. (-121.39%), greater than Avalo Therapeutics, Inc. (-88.43%), less than Protalix BioTherapeutics, Inc. (10.12%), greater than C4 Therapeutics, Inc. (-64.40%), greater than Insight Molecular Diagnostics Inc. (-2898.07%), greater than Sangamo Therapeutics, Inc. (-293.05%), greater than Protara Therapeutics, Inc. (-36.87%),

Build a custom stock screener for Coherus Oncology, Inc. (CHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Coherus Oncology, Inc. (CHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Coherus Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Coherus Oncology, Inc.'s ROE?

How is the ROE calculated for Coherus Oncology, Inc. (CHRS)?

What is the highest ROE for Coherus Oncology, Inc. (CHRS)?

What is the 3-year average ROE for Coherus Oncology, Inc. (CHRS)?

What is the 5-year average ROE for Coherus Oncology, Inc. (CHRS)?

How does the current ROE for Coherus Oncology, Inc. (CHRS) compare to its historical average?